Overview

* Madrigal Q2 2025 net sales rise to $212.8 mln from $14.6 mln year-ago, driven by demand for NASH treatment Rezdiffra

* Co secures new U.S. patent for Rezdiffra, extending protection to 2045

* Madrigal enters global licensing agreement for oral GLP-1 candidate

Result Drivers

* REZDIFFRA DEMAND - Strong demand for Rezdiffra drove Q2 2025 net sales to $212.8 mln, up from $14.6 mln in the prior year period, per CEO Bill Sibold

* PATENT EXTENSION - New U.S. patent extends Rezdiffra's protection to 2045, securing long-term market position, according to CEO Bill Sibold

* PIPELINE ADVANCEMENT - Madrigal announced a global licensing agreement for an oral GLP-1 development candidate, SYH2086, expected to enter clinical trials in H1 2026

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $212.80

Product mln

Revenue

Q2 EPS -$1.9

Q2 Net -$42.28

Income mln

Q2 $260 mln

Operatin

g

Expenses

Q2 -$47.20

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Madrigal Pharmaceuticals Inc ( MDGL ) is $417.50, about 25.2% above its August 4 closing price of $312.11

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)